JP2023500928A5 - - Google Patents
Info
- Publication number
- JP2023500928A5 JP2023500928A5 JP2022526205A JP2022526205A JP2023500928A5 JP 2023500928 A5 JP2023500928 A5 JP 2023500928A5 JP 2022526205 A JP2022526205 A JP 2022526205A JP 2022526205 A JP2022526205 A JP 2022526205A JP 2023500928 A5 JP2023500928 A5 JP 2023500928A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- arenavirus
- virus
- polypeptide
- nucleotide sequence
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962932214P | 2019-11-07 | 2019-11-07 | |
| US62/932,214 | 2019-11-07 | ||
| PCT/EP2020/081393 WO2021089853A1 (en) | 2019-11-07 | 2020-11-06 | Arenaviruses as vectors |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2023500928A JP2023500928A (ja) | 2023-01-11 |
| JP2023500928A5 true JP2023500928A5 (https=) | 2023-11-14 |
| JP7783631B2 JP7783631B2 (ja) | 2025-12-10 |
Family
ID=73198316
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022526205A Active JP7783631B2 (ja) | 2019-11-07 | 2020-11-06 | ベクターとしてのアレナウイルス |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20220380805A1 (https=) |
| EP (1) | EP4055173A1 (https=) |
| JP (1) | JP7783631B2 (https=) |
| CN (1) | CN114981443A (https=) |
| AU (1) | AU2020377504A1 (https=) |
| CA (1) | CA3160032A1 (https=) |
| WO (1) | WO2021089853A1 (https=) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SI2604695T1 (sl) | 2007-12-27 | 2023-03-31 | Universitaet Zuerich Prorektorat Forschung | Replikacijsko defektni arenavirusni vektorji |
| JP6818551B2 (ja) | 2013-12-03 | 2021-01-20 | ホオキパ バイオテック ジーエムビーエイチ | Ｃｍｖワクチン |
| AU2016274655B2 (en) | 2015-06-10 | 2021-06-17 | NeoTrail Therapeutics, Inc. | HPV vaccines |
| DK3373959T3 (da) | 2015-11-12 | 2022-09-19 | Hookipa Biotech Gmbh | Arenaviruspartikler som cancervacciner |
| US20240229073A1 (en) | 2021-05-13 | 2024-07-11 | Hookipa Biotech Gmbh | Arenaviruses as vectors |
| WO2022269362A2 (en) * | 2021-06-21 | 2022-12-29 | Vaxxinova International B.V. | Veterinary viral vector |
| CA3236106A1 (en) | 2021-11-08 | 2023-05-11 | Henning Lauterbach | Modified arenavirus particles expressing mutant kras, mutated cancer driver gene, or tumor-associated antigen as cancer immunotherapies |
| WO2023152116A1 (en) | 2022-02-08 | 2023-08-17 | Hookipa Biotech Gmbh | Combination therapy with arenavirus particles and immune checkpoint modulators or cytokines |
| AU2024343172A1 (en) | 2023-09-15 | 2026-03-05 | Gilead Sciences, Inc. | Arenavirus formulations, methods and uses thereof |
| WO2025191169A1 (en) | 2024-03-15 | 2025-09-18 | Hookipa Biotech Gmbh | Modified arenavirus particles expressing cancer testis antigens as cancer immunotherapies |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5057540A (en) | 1987-05-29 | 1991-10-15 | Cambridge Biotech Corporation | Saponin adjuvant |
| US4912094B1 (en) | 1988-06-29 | 1994-02-15 | Ribi Immunochem Research Inc. | Modified lipopolysaccharides and process of preparation |
| DE102004034461B4 (de) * | 2004-07-16 | 2008-02-07 | Chemotherapeutisches Forschungsinstitut Georg-Speyer-Haus | Gentherapie solider Tumore durch retrovirale, mit Arenavirus-Glykoprotein pseudotypisierte Vektoren |
| US8063063B2 (en) | 2006-03-23 | 2011-11-22 | Novartis Ag | Immunopotentiating compounds |
| ES2536426T3 (es) | 2006-03-23 | 2015-05-25 | Novartis Ag | Compuestos de imidazoquinoxalina como inmunomoduladores |
| SI2604695T1 (sl) | 2007-12-27 | 2023-03-31 | Universitaet Zuerich Prorektorat Forschung | Replikacijsko defektni arenavirusni vektorji |
| EP2968506B1 (en) | 2013-03-15 | 2019-07-31 | Université de Genève | Anti-mycobacterial vaccines |
| JP6818551B2 (ja) | 2013-12-03 | 2021-01-20 | ホオキパ バイオテック ジーエムビーエイチ | Ｃｍｖワクチン |
| SI3218504T1 (sl) | 2014-11-13 | 2020-11-30 | Universite De Geneve | Tri-segmentirani arenavirusi kot vakcinski vektorji |
| AU2016274655B2 (en) | 2015-06-10 | 2021-06-17 | NeoTrail Therapeutics, Inc. | HPV vaccines |
| CA3003557A1 (en) | 2015-11-04 | 2017-05-11 | Hookipa Biotech Ag | Vaccines against hepatitis b virus |
| DK3373959T3 (da) * | 2015-11-12 | 2022-09-19 | Hookipa Biotech Gmbh | Arenaviruspartikler som cancervacciner |
| IL262963B2 (en) | 2016-05-18 | 2025-01-01 | Hookipa Biotech Gmbh | Trisegmented PICHINDE viruses as vaccine vectors |
| US20240229073A1 (en) * | 2021-05-13 | 2024-07-11 | Hookipa Biotech Gmbh | Arenaviruses as vectors |
-
2020
- 2020-11-06 WO PCT/EP2020/081393 patent/WO2021089853A1/en not_active Ceased
- 2020-11-06 CA CA3160032A patent/CA3160032A1/en active Pending
- 2020-11-06 AU AU2020377504A patent/AU2020377504A1/en active Pending
- 2020-11-06 US US17/772,996 patent/US20220380805A1/en active Pending
- 2020-11-06 EP EP20803814.1A patent/EP4055173A1/en active Pending
- 2020-11-06 JP JP2022526205A patent/JP7783631B2/ja active Active
- 2020-11-06 CN CN202080092367.4A patent/CN114981443A/zh active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2023500928A5 (https=) | ||
| JP2020516601A5 (https=) | ||
| JP2021035366A5 (https=) | ||
| JP7783631B2 (ja) | ベクターとしてのアレナウイルス | |
| JP2012500652A5 (https=) | ||
| US20200113995A1 (en) | Arenavirus particles to treat solid tumors | |
| CA2744910C (en) | Replication-defective arenavirus vectors | |
| AU2016352572B2 (en) | Arenavirus particles as cancer vaccines | |
| JP7254018B2 (ja) | ワクチンベクターとしての三セグメントピチンデウイルス | |
| CN107406855A (zh) | 黄病毒复制子 | |
| TW587942B (en) | Polynucleotide vaccine composition against canine pathogens, in particular respiratory and digestive pathogens | |
| Gerson et al. | Gene therapy of cancer: translational approaches from preclinical studies to clinical implementation | |
| Cattoli et al. | Development and preliminary validation of an ad hoc N1-N3 discriminatory test for the control of avian influenza in Italy | |
| US20240229073A1 (en) | Arenaviruses as vectors | |
| He et al. | Baculovirus vector as a delivery vehicle for influenza vaccines | |
| Huang et al. | Rational optimization of glycoprotein E (gE)-encoding mRNA for improved Varicella-zoster virus mRNA vaccine development | |
| Peng et al. | Efficient delivery of DNA vaccines using human papillomavirus pseudovirions | |
| Subba-Reddy et al. | Retraction for Subba-Reddy et al.,“norovirus RNA synthesis is modulated by an interaction between the viral RNA-dependent RNA polymerase and the major capsid protein, VP1” | |
| BR102019025802A2 (pt) | Processo de produção de uma composição imunológica de dna profilática e terapêutica contra hpv e cânceres associados ao vírus, proteína híbrida, vetor de expressão, composição imunológica e seus usos | |
| Martinez-F et al. | 534. Tumorigenic Effect of Transplanted Myoblasts Overexpressing Bcl-2 Based on Retroviral Vector | |
| Yang et al. | Engineering of Vesicular Stomatitis Virus (VSV) for Modulating Cell Death and Antitumor Immunity | |
| Martinez-Sobrido | Replication-Competent Reporter-Expressing Viruses | |
| Blanchard et al. | Endogenous virus and hepatitis C virus-like particle budding in BHK-21 cells | |
| Sun et al. | Hsp90 inhibitors: a potential treatment for latent EBV infection? | |
| PAN et al. | Preparation and efficacy of inactivated vaccine against cyprinid herpesvirus-2 |